Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis

Authors

Ying‐Ming Jou
Brandon Becker (ORCID: https://orcid.org/0000-0002-9232-631X)
Lynda Spelman (ORCID: https://orcid.org/0000-0002-7330-4713)
Misti Linaberry
April Wang Armstrong (ORCID: https://orcid.org/0000-0003-0064-8707)
Alexa B. Kimball (ORCID: https://orcid.org/0000-0001-9405-0479)
Howard Sofen (ORCID: https://orcid.org/0000-0001-7789-6915)
Carolin Daamen
Richard Bruce Warren (ORCID: https://orcid.org/0000-0002-2918-6481)

Institutions

Beth Israel Deaconess Medical Center (US)
University of California, Los Angeles (US)
Manchester Academic Health Science Centre (GB)
Bristol-Myers Squibb (United States) (US)
Los Angeles Medical Center (US)
Veracity Clinical Research (AU)
NIHR Manchester Biomedical Research Centre (GB)

Publication Details

Journal: Dermatology and Therapy
Published: 2025-12-05
DOI: https://doi.org/10.1007/s13555-025-01606-9
Primary Topic: Psoriasis: Treatment and Pathogenesis
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Bristol-Myers Squibb
National Institute for Health and Care Research
Manchester Biomedical Research Centre

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis

Ying‐Ming Jou, Brandon Becker, Lynda Spelman, Misti Linaberry et al.

Dec 5, 2025

Dermatology and Therapy

Psoriasis: Treatment and Pathogenesis

article

Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis

Ying‐Ming Jou, Brandon Becker, Lynda Spelman, Misti Linaberry, April Wang Armstrong, Alexa B. Kimball, Howard Sofen, Carolin Daamen, Richard Bruce Warren

December 5, 2025article en

Abstract

No abstract available for this paper.

Dermatology and TherapyVol. 16(1)

Beth Israel Deaconess Medical Center (US), University of California, Los Angeles (US), Manchester Academic Health Science Centre (GB), Bristol-Myers Squibb (United States) (US), Los Angeles Medical Center (US), Veracity Clinical Research (AU), NIHR Manchester Biomedical Research Centre (GB)

Bristol-Myers Squibb, National Institute for Health and Care Research, Manchester Biomedical Research Centre

Openalex Percentile: Top 56%

Psoriasis: Treatment and Pathogenesis

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis — Ying‐Ming Jou, Brandon Becker, et al. · Dermatology and Therapy (2025) | TGRS Research Map | TGRS